Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life

Laura D Locati, Donata Galbiati, Giuseppina Calareso, Salvatore Alfieri, Susanne Singer, Stefano Cavalieri, Cristiana Bergamini, Paolo Bossi, Ester Orlandi, Carlo Resteghini, Francesca Platini, Roberta Granata, Pasquale Quattrone, Moela Mancinelli, Luigi Mariani, Salvatore Lo Vullo, Lisa F Licitra, Laura D Locati, Donata Galbiati, Giuseppina Calareso, Salvatore Alfieri, Susanne Singer, Stefano Cavalieri, Cristiana Bergamini, Paolo Bossi, Ester Orlandi, Carlo Resteghini, Francesca Platini, Roberta Granata, Pasquale Quattrone, Moela Mancinelli, Luigi Mariani, Salvatore Lo Vullo, Lisa F Licitra

Abstract

Background: The treatment of patients with recurrent and/or metastatic (R/M) salivary gland adenoid cystic carcinoma (ACC) remains an unmet need.

Methods: Patients with R/M disease with a history of clinical or symptomatic disease progression within 6 months and a maximum of 1 previous line of chemotherapy or a multiple kinase inhibitor received oral lenvatinib at a dose of 24 mg/day. The primary endpoint was the objective response rate; secondary endpoints included quality of life (QOL) (according to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items [EORTC QLQ-C30] and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core Module Head and Neck Module [EORTC QLQ-H&N35]), progression-free survival and overall survival, duration of response, and toxicities.

Results: Twenty-eight patients with R/M ACC were enrolled. Among 26 evaluable patients, 3 partial responses (11.5%) were reported. Target lesion reductions between 23% to 28% were observed in 4 of 20 patients with stable disease. Treatment-related adverse events were frequent (all grades, 96%; grade≥3 in 50% of cases according to version 4.03 of the National Cancer Institute Common Terminology Criteria for Adverse Events). The dose of lenvatinib was reduced in 24 patients, whereas in 21 patients the dose was reduced within the first 12 weeks and 4 patients maintained the full dose throughout treatment. The QOL deteriorated between baseline and 6 months with regard to Fatigue and Dry Mouth. There was no evidence of changes in Swallowing and Physical Functioning. At a median follow-up of 29 months, 2 patients remained on treatment, 10 patients were off protocol for disease progression and were alive with disease, and 14 patients had died of disease progression. The median overall survival, progression-free survival, and duration of response were 27 months, 9.1 months, and 3.1 months, respectively.

Conclusions: Lenvatinib appears to have modest activity in ACC. Toxicities are common but manageable and QOL was found to deteriorate in some domains.

Trial registration: ClinicalTrials.gov NCT02860936.

Keywords: adenoid cystic carcinoma; lenvatinib; quality of life; toxicity.

© 2020 American Cancer Society.

References

    1. Van Dijk BA, Gatta G, Capocaccia R, Pierannunzio D, Strojan P, Licitra L; RARECARE Working Group. Rare cancers of the head and neck area in Europe. Eur J Cancer. 2012;48:783-796.
    1. El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, eds. WHO Classification of Head and Neck Tumours. 4th ed. World Health Organization; 2017.
    1. Amit M, Eran A, Billan S, et al. Perineural spread in noncutaneous head and neck cancer: new insights into an old problem. J Neurol Surg B Skull Base. 2016;77:86-95.
    1. Gao M, Hao Y, Huang MX, et al. Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Surg. 2013;42:923-928.
    1. Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12:815-824.
    1. Ho AS, Kannan K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45:791-798.
    1. Liu X, Xu Y, Han L, Yi Y. Reassessing the potential of Myb-targeted anti-cancer therapy. J Cancer. 2018;9:1259-1266.
    1. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M. A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 2007;43:33-36.
    1. Jakob JA, Kies MS, Glisson BS, et al. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015;37:644-649.
    1. Dillon PM, Petroni GR, Horton BJ, et al. A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2017;23:4138-4145.
    1. Keam B, Kim SB, Shin SH, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015;121:2612-2617.
    1. Ho AL, Sherman EJ, Baxi SS, et al. Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma. J Clin Oncol. 2016;34(15 suppl):6096-6096.
    1. Wong SJ, Karrison T, Hayes DN, et al. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016;27:318-323.
    1. Thomson DJ, Silva P, Denton K, et al. Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head Neck. 2015;37:182-187.
    1. Locati LD, Perrone F, Cortelazzi B, et al. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact. Eur J Cancer. 2016;69:158-165.
    1. Ho AL, Dunn L, Sherman EJ, et al. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol. 2016;27:1902-1908.
    1. Tchekmedyian V, Sherman EJ, Dunn L, et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37:1529-1537.
    1. Hammerlid E, Mercke C, Sullivan M, Westin T. A prospective quality of life study of patients with laryngeal carcinoma by tumor stage and different radiation therapy schedules. Laryngoscope. 1998;108:747-759.
    1. Hammerlid E, Bjordal K, Ahlner-Elmqvist M, et al. Prospective, longitudinal quality-of-life study of patients with head and neck cancer: a feasibility study including the EORTC QLQ-C30. Otolaryngol Head Neck Surg. 1997;116:666-673.
    1. Nordgren M, Abendstein H, Jannert M, et al. Health-related quality of life five years after diagnosis of laryngeal carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:1333-1343.
    1. Finizia C, Hammerlid E, Westin T, Lindstrom J. Quality of life and voice in patients with laryngeal carcinoma: a posttreatment comparison of laryngectomy (salvage surgery) versus radiotherapy. Laryngoscope. 1998;108:1566-1573.
    1. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-144.
    1. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. European Organisation for Research and Treatment of Cancer; 2001.
    1. Scalone L, Cortesi PA, Ciampichini R, et al. Health related quality of life norm data of the general population in Italy: results using the EQ-5D-3L and EQ-5D-5L instruments. Epidemiol Biostat Public Health. 2015;12:e11457-1.
    1. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621-630.
    1. Self EM, Bumpous J, Ziegler C, Wilson L, Potts K. Risk factors for hemorrhage after chemoradiation for oropharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2013;139:356-361.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する